Background: Only responding patients benefit from preoperative therapy for locally advanced esophageal carcinoma. Early detection of non-responders may avoid futile treatment and delayed surgery. Patients and Methods: In a multi-center phase ll trial, patients with resectable, locally advanced esophageal carcinoma were treated with 2 cycles of induction chemotherapy followed by chemoradiotherapy (CRT) and surgery. Positron emission tomography with 2-[fluorine-18]fluoro-2-deoxy-d-glucose (FDG-PET) was performed at baseline and after induction chemotherapy. The metabolic response was correlated with tumor regression grade (TRG). A decrease in FDG tumor uptake of less than 40% was prospectively hypothesized as a predictor for histopathological non-response (TRG > 2) after CRT. Results: 45 patients were included. The median decrease in FDG tumor uptake after chemotherapy correlated well with TRG after completion of CRT (p = 0.021). For an individual patient, less than 40% decrease in FDG tumor uptake after induction chemotherapy predicted histopathological non-response after completion of CRT, with a sensitivity of 68% and a specificity of 52% (positive predictive value 58%, negative predictive value 63%). Conclusions: Metabolic response correlated with histopathology after preoperative therapy. However, FDG-PET did not predict non-response after induction chemotherapy with sufficient clinical accuracy to justify withdrawal of subsequent CRT and selection of patients to proceed directly to surgery. 18 F]Fluor-2-desoxy-d-glukose (FDG-PET) wurde vor Therapiebeginn und nach Abschluss der Induktionschemotherapie durchgeführt. Das metabolische Ansprechen wurde mit dem Tumorregressionsgrad (TRG) korreliert. Die Hypothese, dass weniger als 40% Abnahme des Wertes der FDG-Aufnahme ein früher prädiktiver Parameter für das Nichtansprechen sei (TRG > 2), wurde prospektiv geprüft. Ergebnisse: 45 Patienten wurden eingeschlossen. Die mittlere Abnahme der FDG-Anreicherung im Tumor korrelierte gut mit dem TRG nach Abschluss der CRT (p = 0,021). Eine Abnahme der FDG-Anreicherung von weniger als 40% sagte ein Nichtansprechen mit einer Sensitivität von 68% und einer Spezifität von 52% voraus (positiver Vorhersagewert 58%, negativer Vorhersagewert 63%). Schlussfolgerungen: Das metabolische Ansprechen nach präoperativer Therapie korrelierte insgesamt gut mit dem histopathologischen Ansprechen. Die FDG-PET sagte jedoch das Nichtansprechen im individuellen Fall nicht mit ausreichender Sicherheit voraus, um den vorzeitigen Abbruch der CRT und eine direkte Operation zu rechtfertigen.
Summary
Background: Only responding patients benefit from preoperative therapy for locally advanced esophageal carcinoma. Early detection of non-responders may avoid futile treatment and delayed surgery.
Patients and Methods:
In a multi-center phase ll trial, patients with resectable, locally advanced esophageal carcinoma were treated with 2 cycles of induction chemotherapy followed by chemoradiotherapy (CRT) and surgery. Positron emission tomography with 2-[fluorine-18]fluoro-2-deoxy-d-glucose (FDG-PET) was performed at baseline and after induction chemotherapy. The metabolic response was correlated with tumor regression grade (TRG). A decrease in FDG tumor uptake of less than 40% was prospectively hypothesized as a predictor for histopathological non-response (TRG > 2) after CRT. Results: 45 patients were included. The median decrease in FDG tumor uptake after chemotherapy correlated well with TRG after completion of CRT (p = 0.021). For an individual patient, less than 40% decrease in FDG tumor uptake after induction chemotherapy predicted histopathological non-response after completion of CRT, with a sensitivity of 68% and a specificity of 52% (positive predictive value 58%, negative predictive value 63%). Conclusions: Metabolic response correlated with histopathology after preoperative therapy. However, FDG-PET did not predict non-response after induction chemotherapy with sufficient clinical accuracy to justify withdrawal of subsequent CRT and selection of patients to proceed directly to surgery. 
Introduction
Esophageal carcinoma is often diagnosed in the locally advanced stage and is associated with a poor long-term outcomeofonly20-30%survivalat2years.Chemoradiotherapy (CRT)followedbysurgeryhasbeenintegratedintostandard treatment. However, only patients who respond to neoadjuvant therapy and achieve an R0 resection at surgery have a substantiallong-termsurvival,whilenon-respondersmaynot benefit [1] butexperienceadverseeffectsoreventumorprogression.Inthiscontext,earlydifferentiationofnon-responders from responders is desirable to prevent non-responders fromreceivinginefficientchemotherapyanddelayedsurgery. Positron emission tomography with 2-[fluorine-18]fluoro-2-deoxy-d-glucose(FDG-PET)visualizestheenhancedglucose metabolismofviableesophagealtumortissue [2, 3] .Anumber ofstudieshaveaddressedthefeasibilityofmeasuringchanges intumorFDGuptaketomonitorresponseandtopredictthe outcomeofneoadjuvanttreatment.
Promisingresultsforearlyresponseassessmentafterneoadjuvant chemotherapy without concomitant radiotherapy were published for adenocarcinomas of the esophagogastric junction [4] .Metabolicresponsewasdefinedbyaretrospectivelycalculatedcut-offofleast35%decreaseintumorFDG uptake after 14 days of chemotherapy. Metabolic response correlated significantly with clinical and histopathological response, disease-free survival and overall survival (OS). A subsequentstudybythesamegroupprospectivelytestedthis cut-off and confirmed that metabolic non-responders had a low histopathological response rate of only 5% and a poor prognosiscomparedwithresponders [5] .
In contrast, single-center studies of CRT for adenocarcinomaand/orsquamouscellcarcinoma(SCC),designedtoassessthecorrelationbetweenadecreaseintumorFDGuptake andhistopathologicalresponse [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] andsurvival [6, 7, 9, 13, 15] ,haveproducedconflictingresults.AgroupfromMunich, Germany,evaluatedPETfortheresponseassessmentinthe courseofCRTofSCC.TheyfoundPET,aftercompletionof CRTandearlyinthecourseofCRT,tohavesimilarpredictivevaluesforhistopathologicalresponse [9, 15] .
Subsequently, the same group prospectively tested a predefinedcut-offof30%decreaseintumorstandardizeduptake values (SUV) after 2 weeks of CRT. However, the negative predictive value (NPV) for histopathological response remained clearly below 80% and, consequently, did not meet the requirement for a clinically relevant predictive test [16] . Radiation-inducedesophagitis,whichcanmasktreatment-induced reduction of SUV, may confound metabolic response evaluationafterCRT [6, 8, 10, 11, 15] .
This study was designed to quantify metabolic tumor responsewithoutinterferencefromradiation-inducedesophagitis, by determining whether changes in tumor FDG uptake after induction chemotherapy, but prior to CRT, can predict histopathological non-response after completion of neoadjuvanttreatment.Acut-offof40%SUVdecreaseforthediffer-entiationofnon-respondersfromresponderswasprospectively defined, based on data from previous studies [4, 9] . The primaryobjectivewastopredicthistopathologicalnon-response. Secondaryobjectivesweretocorrelatemetabolicresponsewith event-free survival (EFS) and OS and to determine whether metabolicresponsemaybeausefulprognosticparameter.
Patients and Methods

Patients
PET imaging was performed as part of a prospective multi-center phase II trial investigating a cisplatin-and taxane-based regimen of 2 cycles of inductionchemotherapy,followedbyCRTandsurgery(SwissGroupfor ClinicalCancerResearch,SAKK75/02,NCT00072033) [17] .Theprotocol wasapprovedbythelocalethicscommitteesoftheparticipatingcenters. ThestudypopulationconsistedofpreviouslyuntreatedpatientswithhistologicallyconfirmedlocallyadvancedbutresectableSCCandadenocarcinomaofthethoracicesophagusoresophagogastricjunctionclassifiedasclinicalstageT3N0,T1-3N+orT4Nx,accordingtotheAJCCCancerStaging Manual, 6th edition [18] . Written informed consent was obtained for all patients.Contrast-enhancedcomputedtomography(CT)ofthethoraxand abdomenandendoluminalultrasoundoftheesophaguswereperformedin allpatientsbeforePETorPET-CT.PETorPET-CTstagingwasstrongly recommendedinthestudyprotocol,butwasnotmandatorybecausePET scannerswerenotavailableinallregionsofSwitzerland.Patientswithdistantmetastasesdetectedduringpre-treatmentevaluationwereexcluded.
PET Imaging
PET or PET-CT was performed at up to 4 weeks before initiation of induction chemotherapy and after completion of 2 cycles of induction chemotherapyinweek5,beforethestartofCRT( fig.1 ).BothPETscans wereperformedatthesamecenteronthesamePETorPET-CTmachine andunderidenticalconditionsforeachpatient.AllPETscannersfulfilled thequalityrequirementsdefinedbytheSwissSocietyofNuclearMedicineandhadaspatialresolutionof6mmorless.
Patients fasted for at least 6 h before an intravenous injection of 5 MBq FDG/kg bodyweight. The blood glucose level was recorded in all patients.Patientswereexaminedaccordingtothelocalacquisitionprotocolsateachcenter,andacquisitionparameterswerekeptconstantfor bothPETscanswithregardtothetimepointofacquisitionaftertracer injection.MaximumSUV(SUV max )oftheprimarytumorwascalculated tosemi-quantifyFDGtumoruptake.PercentagechangesofSUV max betweenbaselinePETandPETafterinductionchemotherapywerecalculated to quantify metabolic response. PET data were evaluated at each siteandreviewedcentrally.
Preoperative Treatment
The preoperative treatment regimen consisted of induction chemotherapywithintravenouscisplatin75mg/m 2 anddocetaxel75mg/m 2 ondays 1 and 21, followed by radiotherapy (total dose 45 Gy) and concurrent chemotherapy comprising intravenous cisplatin 25 mg/m 2 and docetaxel 20mg/m 2 weeklyfor5weeks.Surgerywasscheduled3to8weeksafter CRT( fig.1) .PatientswithevidenceofnewlydetectedstageM1and/or inoperableT4diseasewerenoteligibleforsurgery.
Criteria for Response
Histopathological response was based on pathological findings after esophagectomy. Specimens were examined according to standardized proceduresinlocalpathologylaboratories,andallspecimenswerecentrallyreviewedattheUniversityofBaselbyanexperiencedpathologist.
Klaeser/Nitzsche/Schuller/Köberle/Widmer/ Balmer-Majno/Hany/Cescato-Wenger/ Brauchli/Zünd/Pestalozzi/Caspar/Albrecht/ vonMoos/Ruhstaller ThehistopathologicalresponsewasclassifiedaccordingtotheMandard classificationoftumorregressiongrade(TRG) [19] .TRG1wasdefined ascompleteregression,TRG2aspresenceofrareresidualcancercells scatteredthroughoutthefibrosis,andTRG>2asincreasednumberof residualcancercells.Patientswithcompleteregression(TRG1)ornearcompleteregression(TRG2)wereclassifiedasresponders,whilepatients withpartialandminimalresponseandnochange(TRG3-5)wereclassifiedasnon-responders,aspreviouslyvalidated [15] .
Acut-offof40%decreaseintumorFDGuptakebetweeninitialand second FDG-PET scan was prospectively hypothesized to discriminate non-respondersfromresponders,basedonpreviouslypublishedoptimal cut-off values for response assessment after chemotherapy and CRT of adenocarcinoma and SCC [4, 9] . More than 40% decrease in FDG uptakefrombaselinetothesecondchemotherapycyclewasconsideredasa metabolicresponsetochemotherapy.
Statistical Methods
Thesensitivity,positivepredictivevalue(PPV),specificity,andnegative predictivevalue(NPV)ofmetabolicnon-response(i.e.lessthan40%de-creaseinFDGuptake)predictingTRG>2wascalculated.Survivalendpointsand95%confidenceintervals(CIs)werecalculatedusingtheKaplanMeiermethod.Thesurvivaltimesofstrata(metabolicrespondersvs.nonresponders, adenocarcinoma vs. SCC, histopathological responders vs. non-responders) were compared with the log-rank test. Overall survival was calculated as the time from registration until death (event) or last follow-up(censored).EFSwascalculatedastimefromregistrationuntil deathorprogression(event)orlastfollow-up(censored).ThereverseKaplan-Meiermethodwasusedtocalculatethemedianfollow-uptime.The difference of means or medians was tested with the t-test or Wilcoxon's test.CalculationsandplotswereperformedwithSAS9.1andS-Plus7.0.
Results
Patient and Tumor Characteristics
Of66patientsenrolledintheSAKK75/02trial,57underwent surgicaltumorresectionandassessmentofhistopathological response.Fromthispopulation,45patientswereincludedin thePETstudy.Theremaining12patientswerenotincluded forthefollowingreasons:baselinePETscansnotperformed (9patients;6becausestudycentersdidnotparticipateinthe PETstudy,1patientrefused,and2scanswerenotcorrectly scheduled), 2 patients could not be evaluated because the primarytumordidnotshowanincreasedFDGuptakeinthe baselinescan,and1patientdidnothavethesecondPET.
Themedianagewas61yearsforpatientswithadenocarcino-ma(range48-71years)and59yearsforthosewithSCC(range 44-70years).Thepatientcharacteristicsarelistedintable1.
Change of Tumor FDG Uptake after Two Cycles of Chemotherapy
The median relative change in FDG uptake after induction chemotherapycomparedwithbaselineuptakewas-53%for patientswithhistologicalcompleteornear-completeresponse (TRG 1/2) and -31% for non-responders with an increased number of residual cancer cells (TRG > 2). This difference wasstatisticallysignificant(Wilcoxon'stest:p=0.021; fig.2 ).
Prediction of Histopathological Non-Response after CRT
The prospectively defined cut-off value of less than 40% decrease in FDG uptake after 2 cycles of induction chemotherapy did not reliably predict pathological non-response aftercompletionofCRT( fig.3) .Theoverallsensitivityand specificity for prediction of non-response were 68 and 52%, respectively,resultinginaPPVof58%andanNPVof63%. The sensitivity, specificity, PPV and NPV for non-response were 60, 50, 64 and 45% for adenocarcinoma and 86, 54, 50 and88%forSCC,respectively.Moreover,nosignificantdifferencesinthepredictionofnon-responseaccordingtoSUV decreasewerefoundbetweenpatientspresentingwithadenocarcinomaorSCC. Of note, only an increase in FDG uptake would provide a markedlybetterPPVthanthepredefinedcut-offoflessthan 40% decrease. However, this accounted for only 5 patients. In addition, 11 patients classified as metabolic non-respondersafterinductionchemotherapy(5adenocarcinoma,6SCC, patientsoriginatingfromdifferentparticipatingcenters)had histological complete or near-complete response after completionofCRT.
Prognostic Significance of Metabolic Response to Treatment
Medianfollow-upwas28months(adenocarcinoma27months, SCC30months).MedianOSwas32.4months(95%CIlower limit 25.7 months). Metabolic responders according to the predefinedcriterionofatleast40%decreaseintumorFDG uptake had a median OS of 36.5 months (95% CI 8.0-36.5 months)comparedwith31.0months(95%CIlowerlimit21.4 months) for non-responders. Median EFS was 22.8 months (95% CI lower limit 7.3 months) for metabolic responders and21.7months(95%CI9.8-28.3months)fornon-responders. Differences in OS and EFS failed to reach significance (log-ranktest).
Discussion
Todate,theutilityofFDG-PETforearlyresponseassessment hasbeenshownonlyafterneoadjuvantchemotherapyalone. Promisingresultsusingretrospectivelycalculatedorprospectively defined cut-off values have been published based on extensive work at a single center [4, 5, [20] [21] [22] , and prospectivemulti-centertrialsareplanned [23] .However,arolefor FDG-PET in the response assessment after combined CRT has not been established and published single-center studies haveshownconflictingresults.Whilesomestudiessuggested a possible correlation between the decrease in FDG tumor uptakeandhistopathologicalresponse [7] [8] [9] 15] ,theseresults were not supported for adenocarcinoma or SCC by other, subsequent trials [10] [11] [12] [13] [14] 16] . Radiation-induced esophagitis correlatesmetabolicallywithFDG-PETinupto60%ofpa-tientsafterradiotherapyandmayexplainobviousdifferences inresponseassessmentafterchemotherapyandCRT [6, 8, 10, 11, 15] . ThepatientsinthecurrentstudyweretreatedwithpreoperativeinductionchemotherapyfollowedbyCRT.Itiscritical to identify non-responders to neoadjuvant treatment so that theycanbescheduledforimmediatesurgery.Nooptimalcutoffvaluesforresponseassessmentinthissettingwereavailable. Therefore, based on previously published studies with optimal cut-off values for response assessment after chemotherapyalone(35%,adenocarcinoma [4] )andaftercompletion of combined CRT (52%, SCC [9] ), it was hypothesized thataprospectivelydefinedcut-offoflessthan40%decrease intumorFDGwouldidentifynon-respondingadenocarcinomaand/orSCCaftercompletionofinductionchemotherapy.
For the whole group, the median change of FDG tumor uptake after 2 cycles of induction chemotherapy correlated significantly with the TRG after completion of CRT (p = 0.021).Theseresultswereinaccordancewiththosepublished forresponseassessmentafterchemotherapyalone [4, 5] but without chemoradiation before surgery. After a median follow-upof28monthstherewasatrendtowardsprolongedOS for metabolic responders vs. non-responders after induction chemotherapy. No differences in EFS were found between metabolic responders and non-responders. Therefore, these results did not confirm previously published single-center studiesdescribingasignificantcorrelationbetweenmetabolic responseandEFSand/orOS [4, 6, 7, 9, 20] .
The hypothesis that FDG-PET with a predefined cutoffoflessthan40%decreaseintumorSUVafterinduction chemotherapy may predict histological non-response and treatmentfailurewasnotproven.ThePPVforpredictionof non-response of 58% was not sufficiently accurate to justify withdrawalofCRTinmetabolicnon-respondersandtoselect patientstoproceeddirectlytosurgery.Aretrospectivecalculationofanoptimalcut-offdidnotimprovetheresults( fig.4) because only an increase in SUV reliably pointed towards non-response. These results were less favorable than those ofotherstudiesofadenocarcinomainwhichthesecondPET wasperformed2weeksafterinitiationofchemotherapyalone (PPV for non-response, 95-100%) [4, 5] . Lordick et al. [20] noted no histological responders among metabolic non-responders(lessthan35%SUVdecrease;responseassessment 2weeksafterinitiationofchemotherapy),whileinthepresent study11of26metabolicnon-responders(5adenocarcinoma,6 SCC,lessthan40%SUVdecrease)hadhistologicalcomplete ornear-completeresponseaftercompletionofCRT(specificity52%; fig.3 ).Apparently,subsequentCRTcantransform somemetabolicnon-respondersafterchemotherapyintohistopathologicalresponders.These11metabolicnon-responders afterinductionchemotherapywithsubsequenthistopathologicalresponse(TRG1/2)aftercompletionofCRThadmedian EFSsimilartoallpatientswithhistopathologicalresponse.It canbeconcludedthathistopathologicalresponsewasabetter predictor of outcome than metabolic response in this study. Brücheretal.reportedpromisingresultsforSCCevaluated3 weeksaftercompletionofCRT(PPVfornon-response100%, witharetrospectivelydefinedcut-offof52%) [9] .However, inafollow-upstudybythesamegroup,usingaprospectively definedcut-offof30%,thePPVfornon-response(64%)did not meet the requirement for a clinically relevant predictive test [16] andwasinthesamerangeasdatafromSongetal. [8] usingasecondPETperformed8weeksafterCRT. Totheauthors'knowledge,thisisthefirststudyprospectivelytestingthepredictiveandprognosticvalueofFDG-PET inesophagealcancerinanationwidemulti-centercontext.A strong point of this study is the assessment of non-response as the objective of clinical relevance using a prospectively defined cut-off of tumor SUV decrease during the course of treatment.AnewapproachusingasecondPETafterinduction chemotherapy and before the onset of combined CRT was evaluated to avoid problems with semi-quantification of tumoractivity,i.e.radiation-inducedesophagitis [10] .Alimitationofthisstudyisthesmallnumberofpatientsandmaybe the combined evaluation of adenocarcinoma and SCC. Recently,separatetrialsforadenocarcinomaandSCChavebeen proposedbecausethethresholdsformeasuringPETresponse mayvary [23] .However,allpatientsinthestudyreceivedidenticaltreatmentandnosignificantdifferencesintheprediction of non-response according to SUV decrease were found betweenadenocarcinomaandSCC.Usingamulti-centerdesign means that the mode of acquisition and the instrumentation were standardized to a lesser degree than would be possible inasingle-centerstudy.Nevertheless,onlyrelativechangesof FDGuptakeinthepre-andpost-treatmentscanswereevaluated,andallacquisitionparameterswerekeptuniforminindividualpatients.Undersuchconditions,nosignificanteffectsof methodologicalvariations,i.e.acquisitionparameters,timing of the acquisition after FDG injection, reconstruction algorithmandmethodofSUVmeasurement,havebeendescribed todate [13, [23] [24] [25] ,indicatingthattheresultsofthistrialcan beregardedasreliable.Consensusrecommendationsforthe use of FDG-PET as an indicator of therapeutic response in multi-center trials, which have been published in the meantime [26] ,hadalreadybeenessentiallyrespectedinthedesign ofthistrial.
In conclusion, metabolic response after induction chemotherapy correlated well with histopathological response after completionofCRT.However,responseassessmentwithFDGPETusingsemi-quantitativeuptakemeasurementwasnotable to predict histological non-response after neoadjuvant treatmentwithsufficientclinicalaccuracytoselectpatientstoproceeddirectlytosurgery.Itremainstobedeterminedwhethera morereliableresponsepredictionmaybepossiblebyemploying recent technical developments including high-resolution PET-CT, partial volume and recovery correction, and kinetic modeling.
